Elevance Health Pays $342 Million to Settle Medicare Advantage Overcharging Allegations
Elevance Health, a prominent provider of Medicare Advantage plans, has remitted over $342 million to the federal government to resolve allegations of years-long overcharging of the Medicare program. The substantial payment, wired to the Centers for Medicare & Medicaid Services (CMS) on May 27, marks a significant development in the ongoing scrutiny of billing practices within the Medicare Advantage industry. Government attorneys revealed the payment in a court filing on June 22, shedding light on a settlement that could signal a new era of enforcement for the federal healthcare program.
Background of the Allegations and CMS Action
The payment by Elevance Health, which insures approximately 2 million individuals under Medicare, directly addresses an enforcement action initiated by CMS in February. In that action, the agency threatened to suspend new enrollments for Elevance’s Medicare Advantage plans unless the company rectified what CMS termed "substantial and persistent noncompliance" with federal regulations. These regulations mandate that health plans submit accurate billing data and promptly return any identified overpayments.
Court records indicate that Elevance Health described the payment as a "remittance of the total overpayment amount" as estimated by government audits. Leslie Porras, a company spokesperson, conveyed to KFF Health News that Elevance Health "continues to engage in constructive dialogue" with CMS and remains "optimistic that a resolution can be reached," emphasizing the company’s valuation of its "longstanding relationship with CMS."
This settlement is reportedly the first instance where CMS has successfully compelled a Medicare Advantage health plan to repay such a substantial sum in alleged overpayments, despite government audits having indicated for years that many health plans have overbilled the program.
Experts Weigh In on the Significance of the Payment
The unprecedented nature of this settlement has drawn attention from healthcare policy experts. David Lipschutz, an attorney with the Center for Medicare Advocacy, a nonprofit public interest law firm, expressed surprise, stating, "I’ve never heard of something like this before. Usually, plans seem to tie everything up and try to delay any repayment of anything for years." This sentiment highlights the perceived inertia that has often characterized the recovery of overpayments from Medicare Advantage organizations.
David Meyers, an associate professor at the Brown University School of Public Health, characterized the payment as "substantial" and a "step in the right direction" toward holding the industry accountable. He further commented, "It’s a big win for CMS to get that much," underscoring the financial and regulatory achievement for the agency.
The Medicare Advantage Landscape and Overpayment Concerns
Medicare Advantage plans, privately managed alternatives to traditional Medicare, have experienced significant enrollment growth. More than 35 million Americans, representing approximately 55% of all individuals on Medicare, are now enrolled in these plans. These plans often offer additional benefits, such as dental, vision, and hearing aid coverage, which are not typically included in traditional Medicare. They can also present a more affordable option for beneficiaries compared to purchasing supplemental insurance policies to cover Medicare’s coverage gaps.
However, the financial implications of Medicare Advantage for taxpayers remain a subject of intense debate. The industry has been the target of numerous whistleblower lawsuits and government investigations alleging that health plans frequently exaggerate the severity of beneficiaries’ health conditions to artificially inflate their payments from Medicare. These allegations are contested by the industry, which asserts that payments are appropriately based on documented patient health. Medicare’s payment structure provides higher rates for sicker patients, but it requires that plans bill only for conditions that are accurately documented in a patient’s medical records.
Historical Context of Overpayment Recovery Efforts
Researchers have consistently concluded that Medicare overpays Medicare Advantage plans billions of dollars annually. These overpayments are often attributed to complex medical coding practices that can lead to higher billed amounts than are genuinely justified by patient care. Whistleblower lawsuits, frequently initiated by former employees of healthcare companies, have historically been the primary mechanism for recovering these alleged overpayments.
A notable prior settlement occurred in January, when Kaiser Permanente agreed to pay $556 million to resolve allegations brought by the Justice Department concerning false claims submitted to the government for medical conditions that patients did not have. This settlement was, at the time, the largest penalty of its kind. Kaiser Permanente stated that it settled the case "to avoid the delay, uncertainty, and cost of prolonged litigation."
In contrast, CMS’s direct efforts to prevent Medicare Advantage plans from overcharging have encountered considerable obstacles. In 2014, CMS withdrew a proposed regulation aimed at curbing overbilling following strong opposition from the industry. Furthermore, even when CMS audits identified tens of millions of dollars in overpayments, the agency recovered only a small fraction of these amounts.
A Potential Shift in CMS Enforcement Strategy
The recent threat by CMS to prevent Elevance from enrolling new members may represent a novel approach to enforcement. Matthew Fiedler, a health policy researcher at the Brookings Institution, acknowledged that the payment from Elevance is "not trivial." However, he cautioned that it constitutes a small percentage of the company’s overall Medicare revenue. Fiedler suggested that making a significant impact on the overpayment issue would necessitate CMS securing "many similar payments" from "every" Medicare Advantage insurer, a scenario he views as uncertain at this stage.
Richard Kronick, a former federal health policy official and professor at the University of California-San Diego, echoed Fiedler’s observation that the payment represents a minor portion of Elevance’s revenue. Nevertheless, he described it as "still a sizable check to write." Kronick posited that the action might indicate "a bit of muscle flexing" by CMS to strengthen its enforcement capabilities.
CMS has not yet provided a statement regarding the payment or its broader implications. It remains unclear from the court records whether this payment will fully resolve the CMS threat to ban Elevance from new enrollments. If the enrollment ban is lifted as a result of this payment, it could be considered a relatively favorable outcome for Elevance. In an April filing with the Securities and Exchange Commission, the company had estimated its "potential exposure" in the case to be approximately $935 million, suggesting the $342 million payment represents less than half of their worst-case scenario estimate.
The Longstanding Legal Battle and Future Outlook
Elevance Health, previously known as Anthem, has been engaged in a dispute with the federal government over its billing practices since 2020. In that year, the Justice Department filed a False Claims Act lawsuit against the company, a case that is still pending. Court filings related to this ongoing lawsuit brought to light Elevance’s payment to CMS.
An email, included as part of the court record, confirms that a company official transmitted the wire transfer of $342,209,085.30 on May 27, explicitly linking the payment to the threatened enrollment ban. The company also asserted that it was contesting the CMS enforcement action, deeming it "unprecedented."
In its defense against the Justice Department’s lawsuit, Elevance has denied any wrongdoing. The company’s legal strategy has included arguing that CMS was aware of its billing practices for years and failed to take action.
Professor Meyers from Brown University suggests that CMS’s success in obtaining payment from Elevance could incentivize further enforcement actions. "It remains to be seen whether this is a sea change," he stated, indicating that the long-term impact on industry-wide practices is yet to be determined. The settlement’s resolution and the ongoing False Claims Act lawsuit will be closely watched for any indications of a broader shift in how CMS addresses alleged overpayments within the Medicare Advantage program.
